Heartseed

  • NEWS
  • PIPELINE
  • TECHNOLOGY
  • ABOUT US
    • CEO Message
    • Purpose
    • Company Profile
    • Management
  • Mission & Values
  • CONTACT
  • JP/EN
  1. HOME
  2. NEWS
  3. 2023

2023

2023319

Media News article about the initiation of a clinical trial of Heartseed was published in Nature Medicine.

2023314

PR Albumedix and Heartseed announce Recombumin® as a critical excipient in the manufacture of Heartseed's HS-001 investigational cell therapy as its first in-human trial commences.

2023216

Congress Takehiko Kaneko, CMO and Head of R&D at Heartseed, is speaking at this year's Next Generation Cardiovascular Drug Development in April 25-27.

2023216

Congress Takehiko Kaneko, CMO and Head of R&D at Heartseed, is speaking at this year's iPSC Manufacturing Summit in May 2-4.

2023210

PR Heartseed and Novo Nordisk announce first patient dosed in clinical study with HS-001 - a cell therapy designed to restore heart function in people with advanced heart failure

1

COMPANY OVERVIEW

To transform treatment of severe heart failure by delivering cardiac regenerative medicine, Heartseed Inc. was founded in 2015. It has also been developing technologies to expand the access of RM.

Company name
Heartseed Inc.
Head Office
The Artcomplex Center of Tokyo #302, 12-9, Daikyo-cho, Shinjuku-ku, Tokyo 160-0015, JAPAN
Contact
contact@heartseed.jp

MORE VIEW

MORE VIEW

MENU

  • Home
  • News
  • PIPELINE
  • TECHNOLOGY
  • About us
  • Mission & Values
  • Contacts

language

  • English
  • Japanese
  • GO TO TOP

Copyright © All Rights Reserved HEARTSEED HEARTSEED